{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-162233","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2025-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.209312+00:00","generated_at":"2026-05-18T04:16:13.445377+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lantheus closes $350M acquisition of Life Molecular Imaging; names Dr. Dinkelborg as Head of R&D","bullets":["Completed acquisition of Life Molecular for $350M cash after adjustments, gaining Alzheimer's PET agent Neuraceq.","Appointed Dr. Ludger Dinkelborg, former Life Molecular CEO, as Head of R&D effective Aug 1, 2025.","Transaction adds commercial infrastructure, R&D capabilities, and international footprint for Alzheimer's radiodiagnostics.","Dinkelborg will oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management, and AI/Biomarkers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-162233","json":"https://secwatch.observer/filing/0001193125-25-162233.json","markdown":"https://secwatch.observer/filing/0001193125-25-162233.md","text":"https://secwatch.observer/filing/0001193125-25-162233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000119312525162233/0001193125-25-162233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000119312525162233/d89717d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T04:16:13.445377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e8710cf9e7a3ff60d9fcb84810b0e4e01513e361","claim":"Lantheus Holdings, Inc. completed an acquisition involving Life Medical Group Limited for $350 million (closed 2025-07-21).","evidence_excerpt":"the Transaction pursuant to the Agreement. In accordance with the Agreement, upon the closing of the Transaction, the Purchaser paid the Seller an upfront cash payment of $350 million (following applicable purchase price adjustments under the Agreement) in exchange for all of the outstanding share capital of Life Molecular. The foregoing description of the","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1521036/000119312525162233/0001193125-25-162233-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Life Medical Group Limited"},{"label":"Consideration","value":"$350 million"},{"label":"Closing","value":"2025-07-21"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}